CTNNB1 and neoplasm: Instead, recreating the DNAJB1-PRKACA fusion using CRISPR-Cas9 in mouse hepatocytes via hydrodynamic tail vein injection resulted in the development of tumors in mouse liver, but with long latency (± 1 year) and lacking some typical FLC features, while co-mutating β-catenin (CTNNB1) accelerates tumor formation19.